IBI362 for weight loss in Chinese adolescents with obesity or overweight
Official title: A Randomized, Double-blind, Placebo-controlled Phase 3 Clinical Trial to Assess the Efficacy and Safety of IBI362 in Chinese Adolescents With Obesity or Overweight(GLORY-YOUNG)
Run by Innovent Biologics (Suzhou) Co. Ltd. · NCT07255209 · Data updated 2026-11-12
This research will see if different doses of IBI362 help Chinese adolescents aged 12–17 with obesity or overweight and weight-related health problems lose weight after diet and exercise did not produce at least a 5 kg reduction.
Quick facts
| Phase | Phase 3 |
|---|---|
| Study type | Interventional |
| Ages | 12 Years to 18 Years |
| Sex | All |
| Enrollment | 180 (estimated) |
| Sponsor | Innovent Biologics (Suzhou) Co. Ltd. Industry-sponsored |
| Locations | 1 site (Hangzhou, Zhejiang) |
| Status | Recruiting |
| Started | December 29, 2025 |
| Main results expected | October 31, 2027 |
| Study ends | October 31, 2028 |
| Registry record updated | January 8, 2026 |
| Trial ID | NCT07255209 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adolescents aged 12 to under 18 in China who meet the WS/T 586-2018 obesity criteria or are overweight with at least one weight-related comorbidity and who did not lose ≥5 kg after ≥12 weeks of diet and exercise.
✕Probably not a fit
Patients with type 1 diabetes, pre-pubertal children (Tanner Stage I), or those with recent bariatric surgery are excluded and are unlikely to benefit from participation in this protocol.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This Phase 3 interventional trial plans to enroll about 180 Chinese adolescents aged 12 to under 18 who have not lost at least 5 kg after at least 12 weeks of diet and exercise. Eligible participants meet national criteria for obesity or are overweight with at least one weight-related comorbidity and will receive one of multiple doses of IBI362 or placebo. Participants will be monitored for changes in body weight and for safety outcomes throughout the treatment period. Key exclusions include prior type 1 diabetes, pre-pubertal status (Tanner Stage I), and recent bariatric surgery.
Why it matters
Potential benefit: If successful, IBI362 could provide an additional medical option to help adolescents lose clinically meaningful weight when lifestyle changes alone have not worked.
How similar studies have gone: Other GLP-1–based weight-loss medications such as liraglutide and semaglutide have shown weight reduction in adolescents, so related pharmacologic approaches have demonstrated success, though IBI362 itself is still under evaluation.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: Participants must meet all of the following inclusion criteria to be enrolled: Key Inclusion Criteria: 1. Male or female participants aged ≥12 years and \<18 years at the time of signing the informed consent/assent form. 2. BMI at screening meeting the obesity criteria defined by "WS/T 586-2018 Screening for Overweight and Obesity in School-Age Children and Adolescents" or meeting overweight criteria plus at least one weight-related comorbidity: prediabetes, type 2 diabetes, hypertension, dyslipidemia, fatty liver disease, or obstructive sleep apnea syndrome. 3. Weight change \<5 kg after ≥12 weeks of diet and exercise alone before screening (per self/parental report). Exclusion Criteria: Key Exclusion Criteria: 1. Prior diagnosis of type 1 diabetes. 2. Pre-pubertal participants (Tanner Stage I). 3. History of (or planned) bariatric surgery (except liposuction/abdominoplasty or acupuncture for weight loss performed \>1 year before screening).
Where it's running
-
The Children's Hospital, Zhejiang University School of Medicine
Hangzhou, Zhejiang, China Recruiting
Study contacts
- Study coordinator: Xiaoyan li
- Email: xiaoyan.li@innoventbio.com
- Phone: 18756032014
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Lean Beef as Part of a Healthy Meal Plan for Adolescent Girls with PCOS/PMOS
This pilot study tests a lean beef–based meal plan to see if it improves blood sugar control and diet quality in adolescent girls with PCOS/PMOS.
-
Once-weekly tirzepatide injections for adults with obesity or overweight and weight-related conditions
This trial will see if once-weekly tirzepatide injections (5 mg, 10 mg, or 15 mg) plus a reduced-calorie diet and increased activity help adults with obesity or overweight (without diabetes) lose and keep off weight compared with placebo.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.